Our experiments demonstrated that MDM2 is an independent prognostic factor for tumor recurrence and further confirmed that MDM2 also modulates the activity of wild-type p53 and its associated apoptotic pathways in the PIT1 lineage. The gene discussed is TP53; the disease is neoplasm.